Sign In
Register
eISSN:2278-5299

International Journal of Latest Research in Science and Technology

DOI:10.29111/ijlrst   ISRA Impact Factor:3.35

A News Letter Sign UP!
EVALUATION OF DISEASE ACTIVITY IN EARLY RHEUMATOID ARTHRITIS TREATED WITH TOCILIZUMAB IN COMBINATION WITH METHOTREXATE: A SINGLE CENTER CROSS-SECTIONAL STUDY IN LANZHOU

Research Paper Open Access

International Journal of Latest Research in Science and Technology Vol.7 Issue 6, pp 8-11,Year 2018

EVALUATION OF DISEASE ACTIVITY IN EARLY RHEUMATOID ARTHRITIS TREATED WITH TOCILIZUMAB IN COMBINATION WITH METHOTREXATE: A SINGLE CENTER CROSS-SECTIONAL STUDY IN LANZHOU

Manisha Bhochhibhoya, Rong Zhu, BinitVaidya, Md. Shahidur Khan, ShenHaili

Correspondence should be addressed to :

Received : 20 December 2018; Accepted : 11 January 2019 ; Published : 29 January 2019

Share
Download 125
View 178
Article No. 10960
Abstract

In this study, we evaluate the clinical efficacy and safety of initial treatment by tocilizumab and methotrexate combination in moderate to severe cases of naive Rheumatoid Arthritis. American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) recommend Tocilizumabwith methotrexate combination or as a monotherapy in the management of RA if disease activity remains moderate or high despite the use of other drugs.Method: A retrospective chart review of a prospectively followed cohort of RA patients treated with tocilizumab and methotrexate was done from March 2016 to December 2018 in a tertiary center in Lanzhou. Result: Majority of patients were females (37/50; 74%), mean age at presentation was 36.3±14.7 years. All the parameters studied showed significant change with DAS28 ESR either at or below the low disease activity range (mean ±SD at 3.1±1.2).Conclusion: Combination of tocilizumab and methotrexate as initial treatment of early RA has significant improvement in disease activity.

Key Words   
Rheumatoid Arthritis, Tocilizumab, Disease Activity, Methotrexate, Interlukin-6

Copyright
References
  1. Cross M, Smith E, Hoy D, Carmona L. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. 2014;73(7):1316-22.
  2. Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW, et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford). 2012;51(4):721-9.
  3. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med. 2007;120(11):936-9.
  4. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861-74.
  5. Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug? Autoimmun Rev. 2014;13(11):1102-8.
  6. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509.
  7. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52(3):232-4.
  8. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162-7.
  9. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96.
  10. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-97.
  11. Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handbook of experimental pharmacology. 2008(181):151-60.
  12. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1-25.
  13. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. 2017;76(6):960-77.
  14. Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73(5):803-9.
  15. Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2015;74(1):35-43.
  16. Miossec P. Rheumatoid arthritis: still a chronic disease. Lancet. 2013;381(9870):884-6.
  17. Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 2008;58(5):1310-7.
  18. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46(6):1443-50.
  19. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586-93.
  20. Monti S, Montecucco C, Bugatti S, Caporali R. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD open. 2015;1(Suppl 1):e000057.
  21. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-84.
  22. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12-9.
  23. Burmester GR, Rigby W, van Vollenhoven R, Kay J, Rubbert-Roth A, Kelman A, et al. OP0041 Tocilizumab (TCZ) in Combination and Monotherapy Versus Methotrexate (MTX) in MTX-Naive Patients (PTS) with Early Rheumatoid Arthritis (RA): Clinical and Radiographic Outcomes from a Randomised, Placebo-Controlled Trial2014. A63-A p.
  24. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968-80.
  25. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263-9.
  26. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-90.
  27. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford). 2004;43(10):1252-5.
To cite this article

Manisha Bhochhibhoya, Rong Zhu, BinitVaidya, Md. Shahidur Khan, ShenHaili , " Evaluation Of Disease Activity In Early Rheumatoid Arthritis Treated With Tocilizumab In Combination With Methotrexate: A Single Center Cross-sectional Study In Lanzhou ", International Journal of Latest Research in Science and Technology . Vol. 7, Issue 6, pp 8-11 , 2018

Responsive image

MNK Publication was founded in 2012 to upholder revolutionary ideas that would advance the research and practice of business and management. Today, we comply with to advance fresh thinking in latest scientific fields where we think we can make a real difference and growth now also including medical and social care, education,management and engineering.

Responsive image

We offers several opportunities for partnership and tie-up with individual, corporate and organizational level. We are working on the open access platform. Editors, authors, readers, librarians and conference organizer can work together. We are giving open opportunities to all. Our team is always willing to work and collaborate to promote open access publication.

Responsive image

Our Journals provide one of the strongest International open access platform for research communities. Our conference proceeding services provide conference organizers a privileged platform for publishing extended conference papers as journal publications. It is deliberated to disseminate scientific research and to establish long term International collaborations and partnerships with academic communities and conference organizers.